We'd appreciate your feedback. Send feedback Subscribe to our newsletters and alerts


Pharmaceutical Sciences and Drug Design

2023 Volume 3

Limited Predictive Performance of Existing Amisulpride PopPK Models: External Validation and Proposal of Model-Based Remedial Regimens for Non-Adherence


,
  1. Department of Pharmacognosy, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.
Abstract

This work sought to assess how well previously published population pharmacokinetic (PopPK) models of amisulpride perform in individuals with schizophrenia using an independent dataset, and to design dosing adjustments suitable for patients who miss or delay their amisulpride doses. A comprehensive literature search of PubMed, Embase, and Web of Science was used to collect PopPK models for comparison. A total of 390 serum samples from 361 hospitalized Chinese adults diagnosed with schizophrenia were used for external evaluation. Predictive accuracy was examined using both prediction-based and simulation-based metrics. When the published models showed limited predictive quality, a revised PopPK model tailored to our cohort was built. Monte Carlo simulations were then applied to explore various non-adherence patterns and assess appropriate corrective dosing strategies.
Among the five models reviewed, four relied on trough data from schizophrenia cohorts, and one incorporated single-dose data from healthy elderly subjects together with trough levels from older individuals with Alzheimer’s disease. Population and individual prediction errors spanned −92.89% to 27.02% and −24.82% to 4.04%, respectively. Simulation-based diagnostics, including NPDE, revealed systematic bias in all evaluated models. Consequently, a refined one-compartment model integrating estimated creatinine clearance (eCLcr) as a covariate influencing apparent clearance (CL/F) was derived. For delayed dosing, when the delay is ≤12 hours, half of the missed dose should be taken immediately before returning to the original schedule; if the delay approaches 24 hours, the regular dosage regimen should be resumed without compensation. Existing models do not show sufficient predictive robustness for use across different clinical centers. Prospective research will be required to substantiate the utility of our revised model before clinical implementation. Model-based simulations offered a structured method to design rational management approaches for missed or postponed doses.


How to cite this article
Vancouver
Nkosi T, Dlamini A. Limited Predictive Performance of Existing Amisulpride PopPK Models: External Validation and Proposal of Model-Based Remedial Regimens for Non-Adherence. Pharm Sci Drug Des. 2023;3:53-66. https://doi.org/10.51847/iAz1QEBpk0
APA
Nkosi, T., & Dlamini, A. (2023). Limited Predictive Performance of Existing Amisulpride PopPK Models: External Validation and Proposal of Model-Based Remedial Regimens for Non-Adherence. Pharmaceutical Sciences and Drug Design, 3, 53-66. https://doi.org/10.51847/iAz1QEBpk0

About GalaxyPub

Find out more

Our esteemed publisher is committed to advancing medical knowledge through rigorous research dissemination. We exclusively accept submissions related to the field of medicine.

Our journals provide a platform for clinicians, researchers, and scholars to share groundbreaking discoveries, clinical insights, and evidence-based practices. By maintaining this specialized focus, we ensure that their publications contribute significantly to the advancement of healthcare worldwide.